The gut microbiome has been implicated in a diversity of diseases, such as irritable bowel syndrome, inflammatory bowel disease, hepatic steatosis, metabolic syndrome, obesity, and anxiety. Current research also suggests the presence of a bidirectional relationship between the composition of the gut microbiome and critical illness. In the critical care setting, multiple factors (eg, use of antibiotics, aberrant nutrition, bloodstream infections, bowel ischemia, and abnormal bowel motility) strongly contribute to intestinal dysbiosis. Conversely, early studies have associated intestinal dysbiosis with worse clinical outcomes in the intensive care unit (ICU), such as infection, organ failure, and mortality. The possibility of intestinal dysbiosis influencing these clinical outcomes has prompted the question of whether microbiome manipulation strategies, such as fecal microbiota transplantation (FMT), may have a role in the management of critical illness. After a literature search of FMT used in the ICU for indications other than Clostridium difficile infections, we found 4 case reports that describe the use of FMT in 5 critically ill patients with systemic inflammatory responses and no clear source of infection. This review discusses the relationship between the gut microbiome and critical illness, early data on the use of FMT in critical care, and safety considerations of FMT in the critically ill and immunocompromised populations. (Nutr Clin Pract. 2019;34:73-79) 
Introduction
The gastrointestinal tract is home to an immensely rich population of bacteria, viruses, and microbial eukaryotes that comprise the gut microbiota. There are an estimated 100 trillion (10 14 ) microbes that account for approximately 2 million genes, compared with the 23,000 genes found in humans. 1, 2 The complex interactions between the gut microbiome, nutrients that traverse the gastrointestinal tract, metabolic byproducts, and the human host contribute to the dynamic equilibrium between health and disease. Although alterations in the gut microbiome have been implicated in diverse disease states (eg, irritable bowel syndrome, inflammatory bowel disease [IBD] , hepatic steatosis, metabolic syndrome, obesity, and anxiety), the cause-effect relationship is challenging to disentangle. [3] [4] [5] [6] On the one hand, many potential confounders (eg, diet, medications, pathogen exposures, and hygiene) can influence the composition of the gut microbiota independent of disease; on the other hand, microbial dysbiosis has previously been shown to alter intestinal permeability, physiologic function, and the metabolic profile, all which can lead to pathology. 7, 8 An early recognition of the putative benefits of exogenous microbes on human health is credited toÉlie Metchnikoff, a Ukranian scientist who won the Nobel Prize in Physiology or Medicine for his seminal work in immunology. Unrelated to this work, Metchnikoff observed that Bulgarian peasants lived particularly long and healthy lives, which he attributed to the consumption of fermented milk. In 1907, he published "The Prolongation of Life," claiming that the consumption of lactic acid-producing bacteria would competitively inhibit more pathogenic bacteria, thus improving health and longevity. He began consuming fermented milk ("Bulgarian Bacillus") and recommended the same for his friends. 9 Although the hypothesis that fermented milk or yogurt containing Lactobacillus bulgaricus reduced senility was never proven, this growing practice introduced the concept of microbiota manipulation to promote health.
Probiotics represent a form of microbiota manipulation through the ingestion of cultured bacterial strains and may impact the development or course of certain diseases. A systematic review of 30 randomized controlled trials (RCTs) involving 2972 critically ill adults found that probiotics reduced the risk of infections and ventilatorassociated pneumonia but not diarrhea, length of stay, or mortality. 10 In a separate meta-analysis of 31 randomized trials, probiotics reduced the risk of Clostridium difficileassociated diarrhea. 11 However, the overall certainty of evidence remains low because of substantial heterogeneity across studies and potential publication bias. The gut colonization potential and durability of probiotics are also unclear. Although concrete recommendations regarding probiotic use in the critical care setting cannot yet be made, the available data show promising benefits of microbiota manipulation on clinical outcomes.
Fecal microbiota transplantation (FMT) presents another and more comprehensive approach to microbiota restoration. The procedure involves the collection of fecal matter-with all its microbial and metabolite constituentsfrom a presumably healthy donor and its administration into the recipient. Unlike the few bacterial strains included in probiotics, FMT stool includes practically all the bacteria, viruses, eukaryotes, and metabolites from the healthy donor. Although the use of FMT to treat food poisoning and severe diarrhea dates back to fourth-century China, the introduction of FMT in the modern era began in 1958 when Eisman et al reported the successful treatment of 4 patients with severe pseudomembranous colitis using enemas from donor feces. 12 This treatment remained dormant until 1983, when a case of C. difficile infection (CDI) was successfully treated with donor feces from the patient's husband, which generated renewed interest in this novel yet controversial strategy. 13 Following a landmark RCT in 2013 demonstrating the superiority of duodenal fecal infusion compared with vancomycin, FMT became established as a cornerstone treatment for recurrent and refractory CDI and is now even recommended by most infectious disease and gastroenterology guidelines. [14] [15] [16] [17] There has been emerging evidence that FMT is effective for other gastrointestinal diseases, and more recently there has been burgeoning interest in its use in the critical care setting.
The Gut Microbiome and Critical Illness
There is a bidirectional relationship between the gut microbiome and critical illness. Several factors in the critically ill patient may contribute to intestinal dysbiosis, such as the use of antibiotics, aberrant nutrition, bloodstream infections, bowel ischemia, and abnormal bowel motility in the setting of immobility and medications. The microbiota in critical illness generally shifts toward dysbiosis, a disequilibrium of bacterial composition that tends to involve a loss of bacterial diversity and disproportionate increase in more pathogenic strains. In a prospective study of 34 patients admitted to the intensive care unit (ICU), critically ill patients experienced a disappearance of the Blautia, Faecalibacterium, Pseudobutyrivibrio, Ruminococcus, and Subdoligranulum genera in the gut. 18 These commensal bacteria are notable for their role in converting fiber into acetate and butyrate, short-chain fatty acids that have antiinflammatory properties and can serve as an energy source for the colonic epithelium. Another prospective study with 32 patients admitted to the ICU under the trauma and acute care surgery service similarly found a disappearance of intestinal Faecalibacterium and Ruminococcus, with replacement by the more pathogenic Enterococcus. 19 There was also an increase in other pathogenic strains in extraintestinal locations, such as Mycoplasma on the tongue and Acinetobacter on the skin.
Although it is possible that the microbiota profiles in these patients serve as surrogate markers of critical illness, emerging evidence also shows that the microbiota can conversely influence disease activity. In a prospective study of 301 patients in the medical ICU, the presence of Enterococcus in the stool at the time of admission was associated with all-cause infection or death. 20 Rectal carriage of certain organisms (Enterococcus, Escherichia coli, C. difficile, Pseudomonas, and Klebsiella) was also associated with subsequent extraintestinal culture-proven infection with the same organism. In mice, the presence of E. coli attenuates the deleterious effects of Salmonella typhimurium in the intestines or Burkholderia thailandensis in the lungs. 21 In an experimental mouse model of renal ischemia and reperfusion, mice inoculated with acetate-producing bacteria had a lower risk of developing acute renal injury. 22 The mechanisms of the microbiome affecting critical care outcomes are unclear, although a few hypotheses exist. For one, the gut microbiota has significant interactions and downstream effects on immunity. Microbial components are recognized by pattern recognition receptors (eg, Toll-like receptors, nucleotide-binding oligomerization domain [NOD]-like receptors), which lead to activation of the immune response. 23 By contrast, shortchain fatty acids, polyamines, and amino acids derived from beneficial bacteria help modulate inflammatory activity. Secondly, commensal bacteria can inhibit adhesion and growth of bacterial pathogens through direct or indirect colonization resistance. 24, 25 Direct colonization resistance involves the production of bacteriocin or other antimicrobial peptides, competitive consumption of nutrients, and competitive colonization of the intestinal mucosa. Indirect colonization resistance involves the induction of the innate and adaptive immune defenses that interfere with the proliferation of bacterial pathogens. A third mechanism relates to a breakdown of intestinal mucosal integrity, leading to bacterial translocation. 8 The benefit of enteral nutrition, even "trophic feeding" at a lower rate, relates to the preservation of the intestinal epithelial barrier and modulation of local gut immunity. [26] [27] [28] Inversely, the absence of oral or enteral nutrition promotes intestinal permeability, which exposes the submucosal immunologic cells to luminal bacteria and/or facilitates bacterial translocation. A metaanalysis of RCTs of nutrition support in ICU patients found enteral nutrition to reduce the risk of sepsis, although a more recent RCT with 2410 ICU patients did not find any difference between early enteral and parenteral nutrition on ICU-acquired infections. 29 Bacteremia was modestly less common among those receiving early enteral nutrition (3% vs 5%) but not statistically significant. Ecologic analysis of the upper respiratory tract in patients with acute respiratory distress syndrome (ARDS) revealed the presence of enteric bacteria (Bacteroides), suggesting the migration of these bacteria toward the lungs. 30 On the other hand, the presence of certain bacterial strains can have protective effects on the gut mucosal barrier. Lactobacillus GG has previously been shown to induce expression of cytoprotective heat shock proteins by intestinal epithelial cells. 31 Lactobacillus salivarius has also been shown to protect the intestinal mucosal barrier from oxidative stress. 32 Given the putative effects of intestinal dysbiosis on gut permeability that lead to increased extraintestinal exposure to toxic molecules, it has been proposed that the gut in critically ill patients acts as a driver of the systemic inflammatory response syndrome (SIRS) and is a major component of the multiple organ dysfunction syndrome (MODS) . 8 This phenomenon is suspected to particularly occur in critically ill patients who experience ARDS, shock, or intractable diarrhea without an identifiable source of infection. For this reason, some have hypothesized that "correcting" the microbiome, such as with FMT, may halt the cycle of harmful substances spreading to the systemic circulation and improve overall clinical outcomes.
Methods
To identify the relevant literature for this narrative review, we performed an electronic search of articles catalogued in PubMed from inception through August 5, 2018, using the following search terms: (["fecal" OR "stool"] AND transplant*) AND ("critical" OR "intensive" OR "severe" OR "sepsis"). Relevant articles were independently identified by title and/or abstract by at least 2 authors. Adjudication was not required, as articles deemed acceptable by at least 1 author were included for full-text review. We also manually reviewed references in the literature related to the use of FMT in critical illness. Inclusion criteria included randomized trials, nonrandomized observational studies, systematic reviews, narrative reviews, and case reports on FMT used in humans. Articles deemed relevant for this review were also included at the discretion of the authors. Exclusion criteria included articles that did not discuss the use of FMT in serious gastrointestinal disease or critical illness and studies that only included animals. Articles that were not published in English were also excluded, although none were superficially found to provide unique information that would otherwise not have been available in the included articles. The search criteria yielded 548 articles of which 66 were eligible for full-text review. Relevant information gleaned from these articles was then used to synthesize the different topic-specific sections of this review.
Results
After a broad literature search, we found 4 case reports that described the use of FMT in 5 critically ill patients (1 teenager and 4 adults) with persistent SIRS and no clear etiology or source of infection (Table 1) . [33] [34] [35] [36] The first 2 cases ever reported came from the same group at Nanjing University (Nanjing, China) in 2014 and 2015. 33, 34 Two subsequent cases were reported by a group at Daping Hospital (Chongqing, China) in 2016, 35 whereas the most recent case was reported by a group at the Medical University of Graz (Graz, Austria) in 2017. 36 The cases shared common features of high fevers, septic shock, and high-volume diarrhea in patients with initially negative infectious cultures and no clear explanation for their severe presentation. One patient had endoscopic and histologic evidence of severe enterocolitis. These symptoms in all 5 patients persisted for weeks despite use of multiple broad-spectrum antibiotics, probiotics, and supportive management. Blood cultures eventually grew Acinetobacter baumannii in 2 patients, Burkholderia cepacia in 1 patient, polymicrobial flora (A. baumannii, Enterococcus faecalis, Propionibacterium acnes) in 1 patient, and no bacteria in 1 patient. The bacteremia with enteric pathogens were felt to stem from an impaired gut mucosal barrier in the setting of pervasive critical illness and were not suspected to be the initial drivers of the sepsis physiology. Because of the unclear etiology, persistence of severe symptoms despite use of powerful antibiotics, and the feature of high-volume diarrhea, intestinal dysbiosis was suspected and tested with 16S rRNA gene-based analytical methods.
The universally abnormal balance of commensal and opportunistic bacteria were key findings that prompted the consideration for empiric FMT. These perturbations typically included decreased amounts of commensal Firmicutes and Bacteroidetes with relative overabundance of opportunistic phyla, such as Proteobacteria. FMT was delivered once by nasoduodenal tube in 2 cases, by nasogastric tube r Significant improvement in diarrhea on post-FMT day 2. r Endoscopic improvement observed on day 7. r Made full recovery and was doing well 97 weeks after discharge. r Short chain fatty acids, including acetate and propionate, increased. r CD4/CD8 ratio returned to normal. ARDS, acute respiratory distress syndrome; CRP, C-reactive protein; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; ESR, erythrocyte sedimentation rate; FMT, fecal microbiota transplantation; IFN-γ , interferon-γ ; IL, interleukin; MODS, multiorgan dysfunction syndrome; Th, helper T cell; TNF-α, tumor necrosis factor-α; UC, ulcerative colitis. in 2 cases, and by colonoscopy in the patient with severe enterocolitis. Remarkably, 4 patients defervesced just 1 day after FMT; the change in temperature was not reported in the remaining patient. Marked improvement in stool output was also soon noticed within 1 to 2 days for 2 patients and within 7 days for 3 patients. All patients had eventual normalization of bowel habits. In the 3 patients where the timeframe was reported, normalization of bowel habits occurred by 16 days after FMT. All patients experienced clearance of blood cultures after FMT.
Given the premise that intestinal dysbiosis drove the patients' SIRS, each patient's stool was subsequently analyzed at various time points after FMT. The follow-up fecal microbiota consistently showed trends in composition resembling that of the healthy donors'. These changes were generally characterized by an expansion of Firmicutes and Bacteroidetes and depletion of Proteobacteria, the inverse of the microbial composition noted prior to FMT. The changes in microbiome occurred as early as day 1 after FMT. These microbial changes strongly correlated with an improvement in clinical parameters, including body temperature, volume of stool output, and stool consistency. One report describes FMT leading to a reduction in inflammatory cytokines, such as interleukin (IL)-1, IL-6, and tumor necrosis factor-α, and a shift in T-helper cell populations toward that of the donor. 34 Another report shows a reduction in systemic inflammatory markers, such as erythrocyte sedimentation rate, C-reactive protein, and procalcitonin, which did not initially respond to standard therapy with antimicrobials.
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Discussion
We present 5 cases reported thus far of patients in the ICU with SIRS and severe diarrhea of unclear etiology persistently unresponsive to broad-spectrum antibiotics who rapidly improved with FMT. The patients defervesced within a day of the procedure, and their stool output began to improve within the first week, as early as the following day. The improvements in clinical parameters were also associated with shifts in the recipients' microbiota patterns toward that of the donors', further attributing the patients' recovery to FMT.
Although these reports of response to FMT show promise for its therapeutic potential in critical illness, there are several caveats to consider. For one, the patients all exhibited a narrowly defined disease process, where there was ongoing intestinal dysfunction and extraintestinal organ failure without an identifiable source of infection. The premise for having FMT performed was the presence of intestinal dysbiosis. We do not yet know whether similar patients would experience benefit with FMT if dysbiosis were absent. We do not know whether patients with dysbiosisgiven how common it is in the critically ill populationwith other identified reasons for SIRS or MODS (eg, central line-associated bloodstream infection, pancreatitis) would improve with FMT. Additionally, we do not know whether patients with dysbiosis but without diarrhea would benefit from FMT. With only 5 patients reported thus far, there is still a large gap of knowledge. These reports nonetheless act as an early proof of concept, and further studies are needed to determine whether FMT is safe and efficacious in an ICU population.
Safety Considerations
Another important consideration prior to the routine implementation of FMT in the ICU is safety. Fortunately, the 5 reported patients did not experience notable adverse effects from the FMT, and there are data that can be extrapolated from other severe conditions. Prior reports of FMT in critically ill patients occurred mostly in the context of CDI, where 1 in 10 patients with CDI requires care in an ICU or colectomy, or dies from CDI. 37 The 2 largest cohort studies to date and the only RCT for severe CDI reported no serious adverse events attributable to FMT in a total of 91 patients with severe-complicated CDI who received FMT. [38] [39] [40] There does not appear to be an observed increase in risk for perforation attributable to colonoscopy-delivered FMT. Aspiration after an upper endoscopic delivery of FMT was reported in 1 case as a complication of general anesthesia, suggesting there should be judicious evaluation of the merits of an upper FMT delivery in the setting of anesthesia and in CDI complicated by ileus. 41 There is 1 report of a patient with recurrent severe CDI complicated by septic shock, who was treated with FMT from a spousal donor through a gastrostomy tube. The patient ultimately developed Pseudomonas aeruginosa, E. coli, and Lactobacillus casei bacteremia, required emergent surgery for pneumoperitoneum from gastrostomy tube migration, and died on day 4 after FMT. The proximal cause of his decline was difficult to ascertain or completely attribute to FMT, but translocation of donor gut flora has been one of the main infectious concerns of FMT. 42 Although there are devastating cases of complications reported, it is important to recognize that most of the adverse events reported in FMT for severe CDI have been nonspecific, self-limited gastrointestinal discomfort. 40 We should also appreciate that the alternative of not considering an FMT in a patient with severe CDI is a well-described surgical risk ranging from 17%-53% with emergent colectomy. 43, 44 FMT should be considered for severe CDI, including patients in the ICU and on mechanical ventilation. The safest and most efficacious route of administration in severe CDI patients has not yet been well elucidated. Theoretically, the risk for colonic perforation is higher in patients with more severe CDI, but the several small available studies do not suggest this to be a major obstacle for performing FMT in severe CDI.
Another vulnerable population in which FMT has been used is immunocompromised recipients. Similar to the concerns of opportunistic infections among the critically ill patients, FMT poses the theoretical risk of causing severe infections in immunocompromised patients. Consequently, most studies and clinical trials for FMT have excluded immunocompromised patients, and there are no guideline recommendations in this population. 14, 15 Nonetheless, there are several case reports of successful FMT in immunocompromised patients as well as a multicenter case series showing no increased risk of adverse events than in an immunocompetent population. [45] [46] [47] In the largest case series of FMT in 80 immunocompromised patients by Kelly et al, 1 patient died from aspiration pneumonia during general anesthesia for colonoscopy. 47 Fourteen percent of patients with IBD in this series suffered an IBD exacerbation after FMT, and 3 underwent colectomy for worsening ulcerative colitis; it should be noted that 2 of these 3 patients had required a colectomy beyond 100 days after FMT, which is unlikely to be related to the FMT. Nonetheless, IBD patients did not have more adverse events than the immunocompromised patients.
Conclusion
The gut microbiome appears to play an integral role in health and disease. Although the causal directionality of intestinal dysbiosis and gastrointestinal disease is difficult to establish, emerging evidence has shown microbiota manipulation strategies to potentially provide benefit. In the critical care setting, patients often have intestinal dysbiosis due to frequent use of antibiotics, infections, ischemia, aberrant nutrition, and abnormal bowel motility. Alterations in the gut microbiome have similarly been associated with worse clinical outcomes in these patients. As such, the use of FMT as a treatment strategy to restore a more favorable microbiome profile and potentially improve clinical outcomes has been proposed. There has been growing experience in the use of FMT for critically ill patients with gastrointestinal disorders. On the other hand, the use of FMT for critically ill patients without gastrointestinal disorders is still limited to 5 cases reported thus far. Although these cases provide a promising proof of concept, there is still an immense dearth of data on safety and efficacy for this ICU population. Nonetheless, there is so far no compelling evidence that FMT would be less safe in the critically ill or immunocompromised population than the general population. Good medical practice still dictates caution: Although these results are reassuring, they are subject to publication bias, and any infectious complication, even if indirectly related to FMT, would be more severe in immunocompromised patients. FMT may represent a novel and exciting frontier in the care of the critically ill patient. However, there is a great need for studies beyond case reports to clarify whether FMT does or does not have a role in critical care.
